Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
These are the reference facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Multiple FDA labelers
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs. Species commonly shown: Both, Dog, Cat.
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Anorexia, Other abnormal test result NOS, Death by euthanasia.
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
Regulatory restrictions are shown in Vet View.
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Marbofloxacin; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 32 reported cases; 27 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Fever (1 reports), Epidermal collarette (1 reports), Elevated total bilirubin (1 reports), Elevated symmetrical dimethylarginine (1 reports), Elevated serum alkaline phosphatase (1 reports)
Digestive (2), Behavior (2), Other (28)
Dog (17 reports), Cat (15 reports)
['Terrier (unspecified)', 'Dog (unknown)'] (2), Boxer (German Boxer) (1), ['Retriever - Labrador', 'Dog (unknown)'] (1), ['Hound (unspecified)', 'Dog (unknown)'] (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Marbofloxacin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
Fever, Epidermal collarette, Elevated total bilirubin
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: February 12, 2026, 10:44 PM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2025-12-15 · MSK · MSK
Received 2025-12-10 · MSK · MSK
Received 2025-11-24 · MSK · MSK
Received 2025-11-17 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 |
Species coverage: Dog (17) Cat (15)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Digestive | Dog | Serious | - | 1 | |
| Behavior | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Behavior | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 |
The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.
Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.
Full source previews and metadata remain in the veterinary/professional layer.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.
For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.
For the treatment of urinary tract infections, Marboquin™ tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin.
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI summary
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 11695-7010-1 | 11695 | - | |
| 11695-7010-2 | 11695 | - | |
| 11695-7011-1 | 11695 | - | |
| 11695-7011-2 | 11695 | - | |
| 11695-7012-1 | 11695 | - | |
| 11695-7013-1 | 11695 | - | |
| 13612-0033-0 | 13612 | - | |
| 13612-0033-1 | 13612 | - | |
| 17033-013-10 | 17033 | - | |
| 17033-013-25 | 17033 | - | |
| 17033-014-10 | 17033 | - | |
| 17033-014-25 | 17033 | - | |
| 17033-015-50 | 17033 | - | |
| 17033-016-50 | 17033 | - | |
| 46066-171-32 | 46066 | - | |
| 46066-171-33 | 46066 | - | |
| 46066-173-32 | 46066 | - | |
| 46066-173-33 | 46066 | - | |
| 46066-175-31 | 46066 | - | |
| 46066-176-31 | 46066 | - |
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
Every non-trivial field is expected to include provenance and update timestamps.
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Cronoquin™ Tablets
RX
Marbofloxacin
Tablet
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-761 | Approved | Feb 2, 2026 |
|
Marbofloxacin
RX
Marbofloxacin
Tablet
• Oral
|
ZYVET AH, Inc. | ANADA 200-736 | Approved | Feb 1, 2023 |
|
Marbofloxacin Chewable Tablets
RX
Marbofloxacin
Chewable Tablets
• Oral
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-733 | Approved | Feb 1, 2023 |
|
Marboquin™
RX
Marbofloxacin
Tablet
• Oral
|
Dechra Veterinary Products LLC | ANADA 200-586 | Approved | Apr 1, 2020 |
|
Zeniquin®
RX
Marbofloxacin
Tablet
• Oral
|
Zoetis Inc. | NADA 141-151 | Approved | Feb 12, 2019 |
Data source: FDA Animal Drugs @ FDA (public search export).
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.
FDA page: Open in Animal Drugs @ FDA
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
FDA page: Open in Animal Drugs @ FDA
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
FDA page: Open in Animal Drugs @ FDA
For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.
The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.
For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.
For the treatment of urinary tract infections, Marboquin™ tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.
FDA page: Open in Animal Drugs @ FDA
For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin.
FDA page: Open in Animal Drugs @ FDA
For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs.
Source: FDA Animal Drugs @ FDA • Reference
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Behavior.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Boxer (German Boxer), Female, 8 year, 27.3 kilogram • Drug: MSK, Tablet, Oral, Dose: 100 Milligram per animal, Frequency: 1 per day • Reactions: Bloody diarrhoea, Elevated lipase, Pancreatitis NOS, Haemorrhagic gastroenteritis, Intentional misuse • Outcome: Ongoing
Dog, ['Retriever - Labrador', 'Dog (unknown)'], Female, 14 year, 26.76 kilogram • Drug: MSK, Tablet, Oral • Reactions: Skin ulcer, Bacterial skin infection NOS, Lack of efficacy (bacteria) - NOS • Outcome: Ongoing
Dog, ['Hound (unspecified)', 'Dog (unknown)'], Male, 14.5 year, 35.83 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Aspiration pneumonia, Lack of efficacy - NOS, Medication error NOS, Anaemia NOS, Mass NOS… • Outcome: Ongoing
Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 9 year, 18.14 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Epidermal collarette, Hepatic toxicosis, Dermal thickening, Pyoderma… • Outcome: Died
Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 9 year, 18.14 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Epidermal collarette, Hepatic toxicosis, Dermal thickening, Pyoderma… • Outcome: Died
Cat, Domestic Shorthair, Female, 11 year, 5.806 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Fever, Lack of efficacy - NOS • Outcome: Ongoing
Cat, Domestic Mediumhair, Female, 11 year, 3.9 kilogram • Drug: MSK, Unknown • Reactions: Elevated betahydroxybutyrate • Outcome: Outcome Unknown
Data source: FDA openFDA Animal & Veterinary adverse event reports.
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.